LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Tryptophan Metabolism Is Dysregulated in Individuals with Fanconi Anemia

By LabMedica International staff writers
Posted on 20 Jan 2021
Print article
Image: Tryptophan metabolism is dysregulated in individuals with Fanconi anemia (Photo courtesy of Cincinnati Children’s Hospital Medical Center).
Image: Tryptophan metabolism is dysregulated in individuals with Fanconi anemia (Photo courtesy of Cincinnati Children’s Hospital Medical Center).
Fanconi anemia (FA) is a complex genetic disorder frequently associated with progressive marrow failure and a strong predisposition to early malignancies, particularly squamous cell carcinomas and hepatocellular carcinomas.

Tryptophan is an essential amino acid necessary for protein synthesis. Tryptophan metabolism has been closely linked to alterations in the microbiome, and dysregulation of the tryptophan pathway has significant implications for host immune regulation, gut inflammation, and overall health.

Hematologists at the Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) and their associates collected blood and stool samples from 23 patients with FA (52% females and age range 5-27 years) and 29 patients with other diagnoses (31% females and age range 1-18). The team studied tryptophan metabolism in FA by examining tryptophan and its metabolites before and during the stress of hematopoietic stem cell transplant (HSCT). Tryptophan can be converted to serotonin and kynurenine.

Plasma levels of tryptophan and metabolites were measured by using an enzyme-linked immunosorbent assay (ELISA): tryptophan (Abnova, Taipei, Taiwan); serotonin and melatonin (Enzo, Farmingdale, NY, USA); kynurenine (BlueGene Biotech, Shanghai, China); transforming growth factor β1 (TGF-β1, R&D Systems, Minneapolis, MN, USA).

Total RNA was isolated from peripheral blood mononuclear cells (PBMCs) and the expression of indoleamine 2,3-dioxygenase, tryptophan hydroxylase 1, and serotonin transporter were measured by RT-qPCR on an Applied Biosystems 7300 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA). The team also performed immunochemistry using a Olympus BX53 microscope (Olympus America, Waltham, MA, USA). Nuclear magnetic resonance was also carried out on the plasma samples.

The scientists reported that that serotonin levels are markedly elevated 14 days after HSCT in individuals with FA, in contrast to individuals without FA. Kynurenine levels are significantly reduced in individuals with FA compared with individuals without FA, before and after HSCT. Most peripheral serotonin is made in the bowel. However, serotonin levels in stool decreased in individuals with FA after transplant, similar to individuals without FA. Instead, the team detected serotonin production in the skin in individuals with FA, whereas none was seen in individuals without FA.

Serotonin and TGF-β levels were closely correlated with platelet count before and after HSCT in persons without FA. In FA, neither baseline serotonin nor TGF-β correlated with baseline platelet count (host-derived platelets), only TGF-β correlated 14 days after transplant (blood bank-derived platelets).

The authors concluded that their findings suggest that serotonin inhibition as a new avenue to diminish a multitude of clinical risks and disease phenotypes in FA, which will now require detailed characterization of local and systemic serotonin metabolism. The study was published on January 7, 2021 in the journal Blood Advances.

Related Links:
Cincinnati Children’s Hospital Medical Center
Abnova
BlueGene Biotech
Thermo Fisher Scientific
Olympus America
Enzo
R&D Systems


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.